⚡ Interrogation des APIs scientifiques en cours…
⚡ Interrogation des APIs scientifiques en cours…
Authors' conclusion
Does not affect the score
Publi-Score
Fidelity
Abstract (PubMed)
A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Overall vaccine efficacy was 70.4% (95.8% CI 54.8-80.6) based on 131 COVID-19 cases in the primary analysis. Efficacy was 62.1% (41.0-75.7) in the SD/SD group and 90.0% (67.4-97.0) in the LD/SD group.
Coeff. authors = avg(0.40, 0.85) = 0.63
Coeff. editorial = avg(1.00, 0.90) = 0.95
min(0.63, 0.95) = 0.63← lowest dominates
Alert signal : eoc → Coefficient forced to 0.3
Expression of Concern published
Alert signal : eoc → Coefficient forced to 0.3
Expression of Concern published
Alert signal : eoc → Coefficient forced to 0.3
Expression of Concern published
Alert signal : eoc → Coefficient forced to 0.3
Expression of Concern published
Final coefficient : 0.63
Final score = 54.3/100 × 0.63 × 100 = 34/100
Adverse events of active and placebo groups in SARS-CoV-2 vaccine randomized trials: A …
Amanzio M — 2022 · Lancet Reg Health Eur
Contrasted resultsNeutralizing antibody levels are highly predictive of immune protection from symptomati…
Khoury DS — 2021 · Nature medicine
Contrasted resultsAssociation Between BNT162b2 Vaccination and Long COVID After Infections Not Requiring …
Azzolini E — 2022 · JAMA
Contrasted resultsMeta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection
Hill A — 2021 · Open Forum Infectious Diseases
Contrasted resultsIvermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Met…
Bryant A — 2021 · American journal of therapeutics